Robbins LLP Is Investigating the Officers and Directors of Carbylan Therapeutics, Inc. (CBYL) on Behalf of Shareholders
Robbins LLP is investigating whether certain officers and directors of Carbylan Therapeutics, Inc. (NASDAQGM: CBYL) violated federal securities laws by issuing materially misleading business information to the investing public. Carbylan Therapeutics is a specialty pharmaceutical company that develops and commercializes novel and proprietary combination therapies.
Carbylan Therapeutics Stock Plunges After Announcing Trial Results
On April 9, 2015, Carbylan held its Initial Public Offering, selling 13 million shares of stock and raising $65 million in new capital. On February 1, 2016, Carbylan disclosed top-line results from COR1.1, its first Phase 3 trial of Hydros-TA for the treatment of pain associated with osteoarthritis of the knee. Carbylan’s stock plummeted following this announcement, and has fallen by 92.8% from its high of $9.22 per share on June 8, 2015, to close at $0.66 per share on March 17, 2016.
Carbylan Therapeutics Shareholders Have Legal Options
Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, or you can complete the form below and we will contact you directly.